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INTRODUCTION
The pathogenic mechanisms underlying ethynylestradiol (EE)-induced cholestasis are still uncertain. More than one mechanism is likely involved in the development of cholestasis by this synthetic estrogen. Due to a decrease in bile saltindependent bile flow (BSIBF) observed in rats, several studies focused their attention on the regulation of the canalicular multidrug resistance-associated protein 2 (Mrp2 or Abcc2) by EE, and found a decrease in its expression (Trauner et al., 1997; Lee et al., 2000) . However, Koopen et al. (1998) demonstrated that impairment in the activity of Mrp2 is not the main cause of EE-induced cholestasis in the rat, because the absence of Mrp2 in TR -rats (hereditarily deficient in Mrp2) did not prevent cholestasis by this estrogen derivative. They concluded that reduction in Mrp2 expression and/or activity does not necessarily represent the key event in the etiology of EE-induced cholestasis.
Sinusoidal multidrug resistance-associated protein 3 (Mrp3 or Abcc3) expression is very low in normal rat and human liver. However, high levels are found in naturally Mrp2-deficient animals (Hirohashi et al., 1998; Johnson et al., 2005) , in animals with obstructive cholestasis (Donner and Keppler, 2001; Soroka et al., 2001) , and in DubinJohnson liver patients (König et al., 1999) . Using Mrp3-null mice, Belinsky et al. (2005) verified that this pump acts as an alternative route for export of bile acids and glucuronides from cholestatic hepatocytes. Hepatic Mrp3 protein is inducible after treatment with different xenobiotics (Owaga et al., 2000; Cherrington et al., 2002; Xiong et al., 2002; Ghanem et al., 2005) leading to an augmented basolateral efflux of common Mrp substrates (Akita et al., 2002; Slitt et al., 2003; Xiong et al., 2002; Ghanem et al., 2005) . Recently, Kamisako and Owaga (2005) Animals and experimental protocols. Adult male Wistar rats (300-350 g) were used throughout. They were maintained ad libitum on a standard laboratory pellet diet and were allowed free access to water during treatment. Animals were randomly divided in two experimental groups. EE-treated rats were administered EE dissolved in propylene glycol (33.7 mM), at a daily dose of 5 mg/kg body wt s.c., for 5 consecutive days (Crocenzi et al., 2001) . Control rats were injected with vehicle (propylene glycol; 0.5 ml/kg body wt s.c.) according to the same schedule as described for EE. All procedures involving animals were conducted in accordance with NIH guidelines for the Care and Use of Laboratory Animals.
Eighteen hr after the last injection of EE or vehicle, bile was collected for determination of bile flow and biliary excretion of bile acids and glutathione as described . At the end of the collection period, the animals were sacrificed by exsanguination, and alkaline phosphatase (ALP; EC 3.1.3.1) determined in serum samples. Livers were perfused in situ with cold saline, removed, and the liver weight/body weight ratio calculated. Portions of hepatic tissue were used for assessment of total glutathione content , preparation of plasma and microsomal membranes, and immunoflourescence studies. prepared from the homogenates by differential centrifugation as described (Carreras et al., 2003) and stored at -70°C until use in western analysis of transporters. Microsomal membranes were obtained from the homogenates as previously described (Catania et al., 1998 ) and stored at -70°C until used in assessment of activity and expression of UDP-glucuronosyltransferase (UGT). Protein concentration was measured using bovine serum albumin as standard (Lowry et al., 1951) .
Western blot studies. Western analysis of Mrp2 was performed in MPM as described . Detection of Mrp3 was performed using a rabbit polyclonal antibody to rat Mrp3 (Ogawa et al., 2000) , as previously described (Ghanem et al., 2005) .
Detection of UGTs was performed in microsomal preparations using a polyclonal antipeptide antibody that specifically recognizes the 1A6 isoform belonging to group 1A as well as an antibody developed against a peptide common to all isoforms of this group (Ikushiro et al., 1995) , as previously reported (Luquita et al., 2001) . Immunoreactive bands were quantified using the Gel-Pro Analyzer (Media Cybernetics, Silver Spring,
Immunofluorescence studies. In situ immunodetection of Mrp3 was performed as described (Ghanem et al., 2005 ) using a Zeiss Pascal LSM confocal system attached to a Zeiss Axioplan 2 imaging microscope.
Mrp3 transport activity in recirculating isolated perfused liver (IPL). To evaluate whether changes in expression of Mrp3 may affect liver secretory function, the
This article has not been copyedited and formatted. The final version may differ from this version. basolateral and apical excretion rates of a model substrate for both Mrp3 and Mrp2 were measured in a different set of animals. The livers were isolated and perfused for 60 min as described . Briefly, the bile duct and portal vein were cannulated (PE10 and Abbocath-®T 14G, respectively) under sodium pentobarbital anesthesia (50 mg/kg body wt, i.p.) and the liver perfused in situ via the portal vein with oxygenated Krebs-Ringer bicarbonate buffer recirculating at a constant flow of 20 ml/min. Basal bile and perfusate samples were collected after a 10-min period of stabilization, then acetaminophen (APAP) was added to the perfusate reservoir (150 ml) in a tracer dose of 2 µ mol/ml of perfusate. APAP is efficiently converted in liver to its glucuronide (APAPglu), which is a substrate for both Mrp2 (Xiong et al., 2000) and Mrp3 (Manautou et al., 2004) . Perfusate samples (100 µ l) were collected at 5-min intervals for 60 min. Bile samples were collected for two 5-min initial periods and then at 10-min intervals for 60 min. At the end of the experiment, the liver was weighed and homogenized (20% w/v in saline). The homogenate (1 ml) was mixed with 70% perchloric acid (50
at 5000 x g for 5 min, and the supernatant used in APAP-glu detection. The content of APAP-glu in bile, perfusate and liver homogenate was determined by HPLC (Howie et al., 1977; Ghanem et al., 2005) . To rule out the possibility that a variation in apical and basolateral excretion of APAP-glu between groups could result from differences in endogenous synthesis of the conjugate, we also determined the activity of UGTs involved in APAP metabolism. UGT activity towards APAP was measured as described (Kessler et al., 2002) 
except that
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RESULTS
Biliary secretory function.
EE treatment caused an increase in the liver weight/body weight ratio with respect to controls (3.83 ± 0.21 vs 3.37 ± 0.06 respectively, p<0.05, n=3), due to both decreased body weight (~8%) and increased liver weight (~5%), as was reported by others (Koopen et al., 1998; Crocenzi et al., 2001; Sánchez Pozzi et al., 2003) . Serum ALP activity also increased in response to EE treatment (333 ± 24 vs 260 ± 47 U/L, for EE and control groups, respectively, p<0.05, n=3). Table 1 shows that the basal bile flow and bile acid and glutathione excretion rates were reduced by EE as reported (Koopen et al., 1998; Crocenzi et al., 2001 , Sánchez Pozzi et al., 2003 , and that the hepatic content of glutathione was not different between groups.
Expression of Mrp2 and Mrp3.
As shown in western blot studies (Fig 1) , Mrp2 protein expression was significantly reduced (-41%) following EE treatment. In contrast, EE produced a marked (+200%) increase in Mrp3 protein expression (Fig 1) . The selective induction of Mrp3 by EE was confirmed by immunoflourescence (Fig 2) . Although no quantitative analysis of Mrp3 expression was performed, these images clearly demonstrate that basolateral immunoreactivity was increased and extended from perivenous to periportal hepatocytes, as was observed in experimental obstructive cholestasis (Donner and Keppler, 2001; Soroka et al., 2001 ).
Mrp3 transport activity in isolated perfused liver (IPL).
The relative contribution of Mrp3 to APAP-glu transport was estimated in IPL. In the current experimental protocol, APAP-glu, the common Mrp2 and Mrp3 substrate, is generated endogenously from the unconjugated parent drug. Because EE was found to modify its own glucuronidation through down-regulation of UGTs (Crocenzi et al., 2001; Sánchez Pozzi et al., 2003) , it was important to rule out the possibility that EE alters APAP glucuronidation. UGT activity towards APAP was not affected by EE treatment (4.19 ± 0.25 vs 3.93 ± 0.33 nmol/min/mg protein, for control and EE groups respectively, n=3). Accordingly, as shown in Fig 1, EE treatment did not affect expression of UGT1A6, the main isoform involved in APAP glucuronidation, nor the intensity of the bands revealed with the 1A antibody that recognizes most relevant isoforms involved in conjugation of phenol derivatives (Ikushiro et al., 1995) . More importantly, the total amount of APAP-glu (bile+perfusate+liver) detected at the end of liver perfusion did not differ between groups (2342 ± 790 and 2320 ± 135 nmol/g liver, 
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DISCUSSION
In the present work, we evaluated the effect of EE pretreatment on the expression and activity of Mrp3 in an attempt to clarify the mechanisms underlying the estrogeninduced impairment in biliary secretory function. In agreement with previous studies (Koopen et al., 1998; Crocenzi et al., 2001; Sánchez Pozzi et al., 2003) , we observed that EE administration decreased bile flow, as a result of a moderate decrease in bile salt excretion and a dramatic reduction in glutathione biliary excretion, the main determinant of bile salt independent bile flow (see Table 1 glutathione by canalicular vesicles (Bossard et al., 1993) , as well as decreased expression of Bsep (Lee et al., 2001; Micheline et al., 2002) and Mrp2 (Trauner et al., 1997; Crocenzi et al., 2001) . Decreased biliary secretion of bile salts is expected to lead to an increase in their intrahepatic levels. However, several findings offer evidence against significant intrahepatic accumulation of bile acids in EE-induced cholestasis.
First, EE-treatment decreases the sodium-dependent taurocholate cotransporter (Ntcp) expression (Simon et al., 1996) , taurocholate uptake in basolateral vesicles (Bossard et al., 1993) , bile salt synthesis (Koopen et al., 1999) and the bile salt pool size (Crocenzi et al., 2001) . Second, the serum ALP level, which is normally increased by intrahepatic bile salt accumulation, is only moderately increased by EE (+28%), in contrast with the significant increase (+160%) observed in obstructive cholestasis (Carreras et al., 2003) .
Because some bile salts are substrates of Mrp3 (Akita et al., 2002) , up-regulation of
Mrp3 by EE could also contribute to reduce their intracellular accumulation. Accordingly, Koopen et al. (1999) and Kamisako and Ogawa (2005) reported increased levels of total bile salts in serum from EE-treated rats.
Normally, hepatic Mrp3 expression is low in rat and humans, but is induced under cholestatic conditions such as bile-duct ligation (Donner and Keppler, 2001; Soroka et al., 2001) , in Mrp2-deficient rats (Hirohashi et al., 1998; Johnson et al., 2005) , after treatment with specific xenobiotics or drugs (Xiong et al., 2002; Slitt et al., 2003; Ghanem et al., 2005) and in Dubin-Johnson patients (König et al., 1999 expression (Cao, et al, 2002) . Estrogen levels accumulate only modestly in pregnancy (from 20 to ~80 pg/ml; Bridges, 1984) , suggesting that the high estrogen levels in EEtreated animals act directly to increase Mrp3 expression.
In contrast to what was reported in rats, Mrp3 is constitutively well expressed in hepatocytes from normal mice, and no induction of Mrp3 mRNA was observed in liver from Mrp2 null mice (Chu et al., 2006) . Interestingly, these authors also found that mRNA and protein expression of basolateral Mrp4 was significantly increased in liver of Mrp2 null mice. It was demonstrated that human MRP4 is also able to transport bile acids (Zelcer et al., 2003) . In consequence, induction of this transporter may represent a compensatory mechanism to deal with reduced apical secretion of these solutes in conditions of altered bile flow formation. In support to this assumption, Denk et al. (2004) have reported up-regulation of Mrp4 in liver from bile duct ligated rats. While induction of Mrp3 and Mrp4 likely compensates for absent or reduced Mrp2 activity in the rat, Mrp4
possibly plays a major compensatory role in mice under these same circumstances.
Whether Mrp4 is induced in response to EE administration, either in rats or mice, remains unknown.
As reviewed by Kroemer and Klotz (1992) , women taking oral contraceptives steroids present a faster elimination of APAP associated with an increased metabolic clearance. This was tentatively explained by stimulation of phase II metabolism of APAP by contraceptive steroids leading to increased urinary elimination of APAP-glu. Recently, we demonstrated increased APAP-glu renal elimination with reduced biliary excretion after repeated administration of APAP to rats (Ghanem et al., 2005 Although the dose of estrogens in contraceptive pills is much lower than that administered to rats to induce cholestasis, women consume contraceptive estrogens chronically and an induction of MRP3 can not be discounted. An eventual preferential basolateral vs apical hepatic excretion of APAP-glu may contribute to explain previous findings in women, as reviewed by Kroemer and Klotz (1992) .
In conclusion, we observed up-regulation of Mrp3 by EE administration in rats, leading to enhanced sinusoidal efflux of APAP-glu. This may represent a compensatory mechanism to prevent intracellular accumulation of common Mrp substrates as a consequence of reduced Mrp2 activity.
